Haploinsufficiency of Apc leads to ineffective hematopoiesis

Blood

Volumn 115, Issue 17, 2010, Pages 3481-3488

  Wang, Jianghong ^a   Fernald, Anthony A ^a   Anastasi, John ^b,c   Le Beau, Michelle M ^a,c   Qian, Zhijian ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW TUMOR; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CHROMOSOME LOSS; COLONY FORMATION; CONTROLLED STUDY; ERYTHROPOIESIS; GENE LOSS; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELL; HETEROZYGOTE; MEGALOCYTOSIS; MONOCYTOSIS; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 77951757238     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-251835     Document Type: Article

References (46)

1. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841-4851.
2. Olney HJ, Le Beau, MM. Cytogenetic abnormalities in myelodysplastic syndromes. Cambridge, MA: Cambridge University Press; 2005.
3. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395. (Pubitemid 351377805)
4. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102(1):43-52. (Pubitemid 36759634)
5. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology. 2004;9(4):271-277.
6. Godley LA, LR. The syndrome of therapy-related myelodysplasia and myeloid leukemia. New York: Marcel Dekker Inc; 2002.
7. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007;2007453-2007459
8. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol. 2007;139(4):578-589. (Pubitemid 350043812)
9. Lai F, Godley LA, Joslin J, et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001;71(2):235-245. (Pubitemid 32165090)
10. Shannon KM, Le Beau MM. Cancer: hay in a haystack. Nature. 2008;451(7176):252-253.
11. Largaespada DA. Haploinsufficiency for tumor suppression: the hazards of being single and living a long time. J Exp Med. 2001;193(4):F15-F18.
12. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
13. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110(2):719-726.
14. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437(7055):147-153. (Pubitemid 41613442)
15. Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13(1):78-83. (Pubitemid 46067389)
16. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1(1):55-67. (Pubitemid 33741881)
17. Akiyama T, Kawasaki Y. Wnt signalling and the actin cytoskeleton. Oncogene. 2006;25(57):7538-7544.
18. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126(5):955-968. (Pubitemid 44310775)
19. Qian Z, Chen L, Fernald AA, Williams BO, Le Beau MM. A critical role for Apc in hematopoietic stem and progenitor cell survival. J Exp Med. 2008;205:2163-2175.
20. Shibata H, Toyama K, Shioya H, et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science. 1997;278(5335):120-123. (Pubitemid 27446290)
21. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269(5229):1427-1429.
22. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91(5):661-672. (Pubitemid 27513657)
23. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404(6774):193- 197. (Pubitemid 30154488)
24. Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006;441(7092):518-522. (Pubitemid 44050154)
25. Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. Biochim Biophys Acta. 1997;1332(2):F25-F48.
26. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261-3273.
27. Socolovsky M. Molecular insights into stress erythropoiesis. Curr Opin Hematol. 2007;14(3):215-224.
28. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001;98(25):14541-14546.
29. Greenberg PL. Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol. 1996;33(2):163-175.
30. Span LF, Rutten E, Gemmink A, Boezeman JB, Raymakers RA, de Witte T. Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions. Leuk Res. 2007;31(12):1659-1667. (Pubitemid 350051409)
31. Raza A, Alvi S, Borok RZ, et al. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. Leuk Lymphoma. 1997;27(1-2):111-118. (Pubitemid 27482927)
32. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20(11-12):891-900. (Pubitemid 27042322)
33. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon- stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108(1):337-345. (Pubitemid 43990647)
34. Nilsson L, Astrand-Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000;96(6):2012-2021.
35. Nilsson L, Eden P, Olsson E, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood. 2007;110(8):3005-3014. (Pubitemid 350006955)
36. Shetty V, Hussaini S, Broady-Robinson L, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood. 2000;96(4):1388-1392. (Pubitemid 30658468)
37. Juvonen E, Aimolahti A, Volin L, Ruutu T. The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. Leuk Res. 1999;23(10):889-894. (Pubitemid 29460823)
38. Ferreira-Cerca S, Poll G, Gleizes PE, Tschochner H, Milkereit P. Roles of eukaryotic ribosomal proteins in maturation and transport of pre-18S rRNA and ribosome function. Mol Cell. 2005;20(2):263-275. (Pubitemid 41484171)
39. Laslo P, Spooner CJ, Warmflash A, et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006;126(4):755-766. (Pubitemid 44233633)
40. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4(7):529-533. (Pubitemid 34752440)
41. Kurki S, Peltonen K, Latonen L, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5(5):465-475. (Pubitemid 38610248)
42. Shiseki M, Kitagawa Y, Wang YH, et al. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leuk Lymphoma. 2007;48(11):2141-2144. (Pubitemid 350091055)
43. Croner RS, Brueckl WM, Reingruber B, Hohenberger W, Guenther K. Age and manifestation related symptoms in familial adenomatous polyposis. BMC Cancer. 2005;524. (Pubitemid 41461104)
44. Rybalov S, Kotler DP. Gastric carcinoids in a patient with pernicious anemia and familial adenomatous polyposis. J Clin Gastroenterol. 2002;35(3):249-252. (Pubitemid 34913093)
45. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol. 2006;7(10):1048-1056. (Pubitemid 44420649)
46. Scheller M, Huelsken J, Rosenbauer F, et al. Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol. 2006;7(10):1037-1047. (Pubitemid 44420648)